Biotech company Imperagen announced on Thursday a £5 million ($6.7 million) seed round led by PXN Ventures, with participation from IQ Capital and Northern Gritstone. The company was founded in 2021 by Manchester Institute of Biotechnology scientists Dr. Andrew Currin, Dr. Tim Eyes, and Dr. Andy Almond and spun out of the university. The startup seeks to improve enzyme engineering by making it faster, more efficient, and less costly than the slower, more physical, trial-and-error-focused proces…
Why this update matters
This developing story is relevant for readers tracking technology because it reflects fresh changes from the original source and signals where attention is shifting next.
Key details
The report was collected automatically and prepared for publication with a newsroom workflow that focuses on clarity, search visibility, and quick understanding.
Readers should review the original source for direct statements, official notices, and any later corrections or additions as the story evolves.
Related coverage
Continue reading with more reporting from the same topic cluster.